SCHEMBL14876908

SCHEMBL14876908

CCOc1cc(/C=C2/S/C(=N/c3ccc(C(=O)O)cc3)N(C)C2=O)ccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 1/20 1.00
▸ ITGAV P06756 1/20 1.00
▸ PTP4A3 O75365 1/20 0.65
▸ FAAH O00519 1/20 0.64
▸ PPARG P37231 1/20 0.62
▸ PTPN1 P18031 2/20 0.60
▸ ACP1 P24666 2/20 0.60
▸ CA9 Q16790 1/20 0.59
▸ ALDH1A1 P00352 4/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ MAPT P10636 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ AURKA O14965 2/20 0.57
▸ AURKB Q96GD4 2/20 0.57
▸ INCENP Q9NQS7 2/20 0.57
▸ FABP4 P15090 1/20 0.55
▸ CSF1R P07333 1/20 0.54
▸ PIK3CG P48736 1/20 0.54
▸ MAP3K19 Q56UN5 1/20 0.54
▸ PIP4K2C Q8TBX8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14876911 1.00 ITGB3 (1.00) ITGB3ITGAVPTP4A3FAAHPPARG
SCHEMBL12717615 1.00 ITGB3 (1.00) ITGB3ITGAVPTP4A3FAAHPPARG
SCHEMBL14876910 1.00 ITGB3 (1.00) ITGB3ITGAVPTP4A3FAAHPPARG
SCHEMBL14883359 1.00 ITGB3 (1.00) ITGB3ITGAVPTP4A3FAAHPPARG
SCHEMBL12717769 0.93 ITGB3 (0.86) ITGB3ITGAVPTP4A3FAAHPPARG
SCHEMBL16000777 0.92 ITGB3 (0.85) ITGB3ITGAVPTP4A3FAAHPPARG
SCHEMBL23519101 0.79 MEN1 (0.68) ITGB3ITGAVPTPN1ACP1ALDH1A1
SCHEMBL30117305 0.79 PTP4A3 (1.00) ITGB3ITGAVPTP4A3PPARGALDH1A1
SCHEMBL19481522 0.79 FAAH (0.84) ITGB3ITGAVFAAHCA9ALDH1A1
SCHEMBL19485870 0.79 FAAH (0.84) ITGB3ITGAVFAAHCA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249191-A1 Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases AVIENNE PHARMACEUTICALS GMBH (AT) 2014-09-04 — — US disclosed
US-20130102645-A1 Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases AVIENNE PHARMACEUTICALS GMBH (AT) 2013-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102645-A1 Methods and compositions for controlling vascularization in ophthalmological and dermatological diseases KDR, REN, FLT1 ITGB3 2036/4885ITGAV 1978/4885PTP4A3 399/4885
US-20140249191-A1 Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases FLT1, KDR, FLT4 ITGB3 2012/4885ITGAV 1557/4885PTP4A3 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback